Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 14615745.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report the successful use of anti-CD20 therapy in a child with refractory myasthenia gravis (MG), an antibody-mediated autoimmune disease, who did not respond to conventional therapy. After initiation of anti-CD20 therapy, clinical improvement (muscular strength, pulmonary function) was observed.
Medical subject headings
- Antibodies, Monoclonal
- Antineoplastic Agents
- Myasthenia Gravis